UCB SA (OTCMKTS:UCBJF – Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as $194.76 and last traded at $194.76, with a volume of 0 shares changing hands. The stock had previously closed at $194.76.
UCB Stock Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $180.54 and a two-hundred day moving average price of $156.04.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Articles
- Five stocks we like better than UCB
- Trading Stocks: RSI and Why it’s Useful
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Compound Interest and Why It Matters When Investing
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- The Most Important Warren Buffett Stock for Investors: His Own
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
